Open AccessGeneration of Recombinant SARS‐CoV‐2 Using a Bacterial Artificial Chromosome
Author(s) -
Chiem Kevin,
Ye Chengjin,
MartinezSobrido Luis
Publication year - 2020
Publication title -
current protocols in microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 35
eISSN - 1934-8533
pISSN - 1934-8525
DOI - 10.1002/cpmc.126
Subject(s) - biology , bacterial artificial chromosome , covid-19 , recombinant dna , virology , pandemic , coronavirus , computational biology , virus , genetics , gene , genome , infectious disease (medical specialty) , medicine , disease , pathology , outbreak
SARS‐CoV‐2, the causative agent of COVID‐19, has been responsible for a million deaths worldwide as of September 2020. At the time of this writing, there are no available US FDA−approved therapeutics for the treatment of SARS‐CoV‐2 infection. Here, we describe a detailed protocol to generate recombinant (r)SARS‐CoV‐2 using reverse‐genetics approaches based on the use of a bacterial artificial chromosome (BAC). This method will allow the production of mutant rSARS‐CoV‐2—which is necessary for understanding the function of viral proteins, viral pathogenesis and/or transmission, and interactions at the virus‐host interface—and attenuated SARS‐CoV‐2 to facilitate the discovery of effective countermeasures to control the ongoing SARS‐CoV‐2 pandemic. © 2020 Wiley Periodicals LLC. Basic Protocol : Generation of recombinant SARS‐CoV‐2 using a bacterial artificial chromosome Support Protocol : Validation and characterization of rSARS‐CoV‐2